Idogen

Be the first to follow this company

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection.

ShowingAll content types

Regulatory press release7/7/2023, 2:01 PM

Idogen avlistas från Nasdaq First North

Regulatory press release7/7/2023, 2:01 PM

Idogen has been delisted from First North Growth Market

Regulatory press release7/7/2023, 10:01 AM

Idogen har försatts i konkurs

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release7/7/2023, 10:01 AM

Idogen has been declared in bankruptcy

Regulatory press release7/7/2023, 5:54 AM

Idogen har lämnat in en formell ansökan om konkurs

Regulatory press release7/7/2023, 5:54 AM

Idogen has submitted a formal application for bankruptcy

Regulatory press release6/8/2023, 12:01 PM

Kommuniké från årsstämma i Idogen AB den 8 juni 2023

Regulatory press release6/6/2023, 11:04 AM

Idogen's Board of Directors proposes that liquidation is not to be resolved at the Annual General Meeting on June 8.

Regulatory press release6/6/2023, 11:04 AM

Idogens styrelse föreslår att likvidation inte beslutas på årsstämman 8 juni

Regulatory press release5/30/2023, 6:03 AM

Idogen working for a sale of its proprietary technology platform

Regulatory press release5/30/2023, 6:03 AM

Idogen arbetar för att sälja sin egenutvecklade teknologiplattform

Press release5/10/2023, 12:25 PM

Penser Future: En sannolik likvidation på gång - Idogen

Press release5/10/2023, 6:36 AM

Redeye: Idogen - Q1 2023 – In a tough situation

Regulatory press release5/9/2023, 7:41 AM

Idogen offentliggör årsredovisning för 2022 med oren revisionsberättelse

Regulatory press release5/9/2023, 6:46 AM

Kallelse till årsstämma i Idogen AB

Regulatory press release5/9/2023, 6:31 AM

Idogen publicerar delårsrapport för 1 januari - 31 mars 2023

Regulatory press release4/28/2023, 6:02 AM

Idogen in discussions about a reversed merger. The company intends to add an agenda item at the annual general meeting on June 8 for possible liquidation

Regulatory press release4/28/2023, 6:02 AM

Idogen är i diskussioner kring omvänt förvärv. Bolaget avser att lägga till en beslutspunkt vid årsstämman 8 juni för möjlig likvidation

Regulatory press release4/18/2023, 6:01 AM

Idogen undersöker omvänt förvärv för att undvika risk för likvidation

Regulatory press release4/18/2023, 6:01 AM

Idogen is investigating reverse acquisitions to avoid risk of liquidation

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.